This is a snippet of the transcript, sign up to read more.
The pandemic has significantly altered the supply chain environment for at least the next 18 months. OEMs, like Honeywell and GE, are struggling to deliver, stating they're still 18 months away from returning to their previous state. PMA providers, however, continue to deliver parts. They don't need to deliver tens of thousands; they only need to deliver hundreds. They can find raw materials and shops that will build these parts in small runs. Once a PMA part is approved and purchased, it resets the bar for that part, making it difficult to return to OEM prices. These parts almost become an annuity, and it's a part-by-part deal.
This is a snippet of the transcript, sign up to read more.
Yes, because airlines typically won't approve a second PMA as it takes the same amount of engineering resources to get the incremental 5% or 6% they might get out of a second PMA, versus the 35% or 40% they'll get from another unique PMA. Unless there's a quality escape or a supply chain constraint, they don't typically approve a second PMA.
This is a snippet of the transcript, sign up to read more.
One thing they did better than Heico was hiring Scott Herndon to run their defense business. Wencor had a $10 million defense business for 12 years, which was steady but sleepy. After hiring Scott, they acquired ASC in Texas, which was worth $30 million, and another small company. Their distribution defense business will likely reach $100 million by the end of next year.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research